Vitamin D3 for Life

Live Enlightened

Article

Plasma Transport of Vitamin D Metabolites: Evidence Synthesis

Previous related pageParacrine Vitamin D Signalling: Full StudyNext related pageVariability in Vitamin D Measurements
Study at a glance

How does vitamin D travel through the blood?

Forms of vitamin D travel mainly attached to proteins or fat-carrying particles. Vitamin D-binding protein carries most of the longer-lasting 25-hydroxyvitamin D, the form measured in the usual blood test. Other carriers also contribute.

Does vitamin D from skin enter the same transport system as vitamin D taken by mouth?

The routes differ at first. A small human study found skin-made vitamin D3 mainly attached to vitamin D-binding protein. Vitamin D2 taken by mouth also travelled with fat-carrying particles. This transport finding does not establish that one source has better health effects.

Why does attachment to proteins matter?

Being attached to a carrier affects how long forms of vitamin D remain in blood and how quickly they reach other parts of the body. It helps maintain a reserve in the blood, but it does not explain every tissue’s access to vitamin D.

Read the full article below ↓

What plasma transport has to accomplish

Vitamin D compounds are hydrophobic molecules, so movement through an aqueous circulation depends heavily on carrier proteins and lipoprotein particles. The important physiological point is that “vitamin D transport” is not one uniform process. Carrier partitioning changes with the molecular form being transported and, for parent vitamin D, with how it entered the circulation. That distinction affects how quickly material leaves plasma, reaches the liver, persists in the circulating reservoir and becomes available for later metabolism.

DBP dominates the long-lived circulating system

Human tracer studies established an early kinetic distinction between parent vitamin D and its 25-hydroxylated metabolite. Vitamin D3 disappeared relatively rapidly from plasma, whereas the polar metabolite with the properties of 25-hydroxyvitamin D persisted much longer. Fractionation experiments placed most of the circulating radioactivity associated with the metabolite in a specific high-density protein fraction rather than in the major lipoprotein fractions. This work helped establish vitamin D binding protein (DBP) as the principal high-affinity plasma carrier for hydroxylated vitamin D metabolites.

That dominance should not be converted into the stronger claim that DBP is the only carrier. Albumin binds a smaller fraction of circulating hydroxylated metabolites, and parent vitamin D can have a materially different early transport history.

Route of entry changes parent-vitamin-D transport

Direct human experiments comparing cutaneously generated vitamin D3 with orally administered vitamin D showed that source matters. After ultraviolet-B exposure, newly synthesized vitamin D3 appeared in plasma almost exclusively in association with DBP. By contrast, orally administered vitamin D was distributed substantially between DBP and chylomicron/lipoprotein fractions during the post-absorptive period.

That difference is physiologically coherent. Vitamin D absorbed from the intestine enters the circulation through lipid-transport machinery, whereas vitamin D released from skin does not pass through the same intestinal chylomicron phase. The two routes therefore converge on the vitamin-D transport system from different starting points rather than producing identical immediate plasma partitioning.

Binding changes kinetics, not just solubility

DBP should not be viewed as inert packaging. Strong carrier binding expands the circulating reservoir and slows loss of vitamin D metabolites from plasma. Experimental absence of DBP produces extremely low circulating 25-hydroxyvitamin D concentrations and more rapid clearance, yet biological vitamin-D action is not abolished. That combination is important: DBP is a major determinant of circulating persistence and buffering, but it is not an absolute prerequisite for every biological action of vitamin D metabolites.

This reservoir function also helps explain why total circulating concentration and immediate tissue access are related but not interchangeable concepts. A large protein-bound pool can support persistence while only a small fraction is unbound at any moment. The distinction is developed further in Free vs Total Vitamin D Explained.

What the evidence does and does not establish

The strongest synthesis is therefore conditional rather than absolute. DBP is the dominant high-affinity carrier for most circulating hydroxylated vitamin D metabolites. Albumin contributes a smaller binding pool. Parent vitamin D can additionally travel in chylomicrons and other lipoprotein fractions, especially after oral absorption. Cutaneously synthesized vitamin D3 enters the plasma transport system differently and is carried predominantly by DBP.

These carrier systems alter residence time, reservoir size and delivery kinetics. They do not by themselves tell us how every tissue acquires vitamin D metabolites from blood. That requires a separate tissue-delivery question within the wider story of vitamin D in the body, because some tissues can access carrier-bound substrate through specialised uptake mechanisms while others may depend more strongly on the free fraction.

Primary evidence and publication details

Smith JE, Goodman DS. The turnover and transport of vitamin D and of a polar metabolite with the properties of 25-hydroxycholecalciferol in human plasma. J Clin Invest. 1971;50:2159-2167.

Haddad JG, Matsuoka LY, Hollis BW, Hu YZ, Wortsman J. Human plasma transport of vitamin D after its endogenous synthesis. J Clin Invest. 1993;91:2552-2555.

Safadi FF et al. Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein. J Clin Invest. 1999;103:239-251.

Related reading

Original sources